Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. April 2019 07:00 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

THE WOODLANDS, Texas, April 02, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the...
22. März 2019 14:16 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Host Conference Call and Webcast Today, March 22, 2019 to Provide a Regulatory Update on Sotagliflozin in Type 1 Diabetes

THE WOODLANDS, Texas, March 22, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that management will conduct a conference call and live webcast today, Friday,...
22. März 2019 14:16 ET | Quelle: Lexicon Pharmaceuticals, Inc.

FDA Issues Complete Response Letter for Zynquista™ (sotagliflozin)

PARIS and THE WOODLANDS, Texas, March 22, 2019 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application for...
15. März 2019 10:39 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Dosing of First Patient in TELE-ABC Study, a Phase 2a Clinical Study of Telotristat Ethyl in Biliary Tract Cancer

THE WOODLANDS, Texas, March 15, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today dosing of the first patient in the Telotristat Ethyl for Advanced Biliary Tract...
13. März 2019 07:00 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides a Business Update

XERMELO® (telotristat ethyl) 2018 U.S. Net Sales Reached $25.0 Million Sotagliflozin in Type 1 Diabetes: March 22 PDUFA Date in U.S., European Commission Decision Expected in Q2 2019 Following...
11. März 2019 16:00 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Financial Results Conference Call and Webcast on March 13, 2019

THE WOODLANDS, Texas, March 11, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter and full-year 2018 financial results on Wednesday, March 13,...
11. März 2019 07:00 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

THE WOODLANDS, Texas, March 11, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and...
01. März 2019 08:00 ET | Quelle: Lexicon Pharmaceuticals, Inc.

CHMP Recommends Zynquista™ (Sotagliflozin) for the Treatment of Adults With Type 1 Diabetes

PARIS and THE WOODLANDS, Texas, March 01, 2019 (GLOBE NEWSWIRE) -- The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the...
28. Februar 2019 17:26 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Poster Presentations at the 16th Annual ENETS Conference

THE WOODLANDS, Texas, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from two posters highlighting XERMELO® (telotristat ethyl) will be...
17. Januar 2019 18:20 ET | Quelle: Lexicon Pharmaceuticals, Inc.

FDA Advisory Committee Votes on Zynquista™ (sotagliflozin) as Treatment for Adults With Type 1 Diabetes

PARIS and THE WOODLANDS, Texas, Jan. 17, 2019 (GLOBE NEWSWIRE) -- The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) today voted eight to eight...

Vorherige Seite